PPI Sequencing Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00384592
Recruitment Status : Completed
First Posted : October 6, 2006
Last Update Posted : March 11, 2009
Information provided by:

October 5, 2006
October 6, 2006
March 11, 2009
September 2006
May 2007   (Final data collection date for primary outcome measure)
The primary objective of this study is to assess the change in the frequency of heartburn from baseline value at entry to the end of the study, after 8-weeks treatment with esomeprazole 40mg compared to previous full dose treatment with a PPI daily
Same as current
Complete list of historical versions of study NCT00384592 on Archive Site
  • Change in frequency and severity of heartburn, epigastric pain and acid regurgitation after 4 and 8 weeks treatment from baseline value at study entry
  • Change in symptom control from baseline to 4 and 8 weeks using QOL questionnaires
Same as current
Not Provided
Not Provided
PPI Sequencing Study
A Study to Assess the Effectiveness of Esomeprazole 40 mg Once Daily in Subjects With Continuing Gastroesophageal Reflux Disease (GORD) Symptoms Following Treatment Wit a Previous Full Dose Proton Pump Inhibitor (PPI)
The purpose of this study is to assess how patients with gastro-oesophageal reflux disease (heartburn) who are currently receiving treatment with a proton pump inhibitor but are still experiencing symptoms will benefit from a change in treatment.
Not Provided
Phase 4
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Gastro-Oesophageal Reflux Disease
  • Drug: Esomeprazole
  • Procedure: Physical exam
  • Procedure: Pregnancy test if applicable
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
May 2007
May 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Persisting symptoms of GORD despite previous treatment with a full dose proton pump inhibitor
  • Informed consent
  • Over 18 years of age

Exclusion Criteria:

  • Current course of Proton Pump inhibitor treatment for more than 8 weeks prior to enrolment in the study;
  • More than 1 other course of PPI treatment in the previous 12 month;
  • Previous use of esomeprazole;
  • Presence of alarm symptoms.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: Rhiannon Rowsell, MD AstraZeneca
Principal Investigator: Roger Jones, MD UCL
March 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP